APR TD012 - Hailey Hailey Disease

Discover who we are and our partners global network, as well as learn more about our people.

Learn more about our products and how they provide innovative solutions for patiens' unmet needs.

Discover our capabilities in project design services.

Find information such as website news, press releases and event presentations.

Get in touch with us to set up a meeting or propose your cooperation.

APR TD012

Hailey Hailey Disease

APR TD012 is a clinical stage drug candidate for the treatment of wounds in Hailey Hailey Disease (HHD) patients. The product improves healing process thanks to its bioburden control and its anti-oxidant properties.

Oxidative stress has been demonstrated to play a specific role in the pathogenesis of HHD by regulating the expression of factors playing an important role in keratinocyte proliferation and differentiation.

Preliminary pre-clinical data suggest that our product could be able to shift the oxidation reduction (redox) balance, leading to a protective antioxidant response.

In addition, thanks to Hypochlorous acid (HClO) presence APR-TD012 could exert a strong antimicrobial activity inactivating one of the most common causes of skin infections in the HHD lesions, which is Staphylococcus aureus.

TEHCLO® TECHNOLOGY

Tehclo™ is the globally patented nanotechnology platform applied to the production of unique hypochlorous acid solutions that ensures the most consistent quality for best-in-class clinical outcomes.

The nanotechnology applied drives electrolysis using a current several times stronger than other standard electrolysis process, minimizing chloride requirements and producing acid oxidizing solution with >95% hypochlorous acid (HClO) purity and 0% hypochlorite (OCl^-) as well as the lowest pH range (2.5-3.0) and high ORP (>1100 mv).

APR TD011 – Epidermolysis Bullosa		APR 1204 – Ocular Surface Diseases